SCHEMBL5448449

SCHEMBL5448449

O=C(NO)c1cc(CSc2ccc(F)cc2)on1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
THRB P10828 1/20 0.48
DAO P14920 1/20 0.48
HDAC6 Q9UBN7 6/20 0.45
L3MBTL1 Q9Y468 2/20 0.44
ALDH1A1 P00352 2/20 0.44
HPGD P15428 1/20 0.44
MAPT P10636 2/20 0.44
TDP1 Q9NUW8 2/20 0.43
LMNA P02545 2/20 0.43
RAB9A P51151 2/20 0.43
RECQL P46063 1/20 0.43
NPC1 O15118 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
CYP2C9 P11712 2/20 0.42
CYP2C19 P33261 2/20 0.42
CYP3A4 P08684 1/20 0.42
HDAC1 Q13547 3/20 0.42
HDAC3 O15379 1/20 0.42
HDAC2 Q92769 1/20 0.42
HDAC10 Q969S8 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5451531 0.86 MEN1 (0.56) DAOHDAC6L3MBTL1ALDH1A1HPGD
SCHEMBL5453519 0.86 MEN1 (0.54) HDAC6ALDH1A1TDP1LMNARAB9A
SCHEMBL5458978 0.86 PPARD (0.51) THRBHDAC6TDP1LMNARAB9A
SCHEMBL5449783 0.85 DAO (0.48) THRBDAOL3MBTL1ALDH1A1HPGD
SCHEMBL14582444 0.83 ALDH1A1 (0.48) HDAC6ALDH1A1HPGDMAPTLMNA
SCHEMBL5460232 0.82 HDAC6 (0.59) DAOHDAC6L3MBTL1HPGDTDP1
SCHEMBL5454441 0.79 HDAC6 (0.46) HDAC6L3MBTL1HPGDMAPTTDP1
SCHEMBL5446344 0.78 L3MBTL1 (0.60) HDAC6L3MBTL1ALDH1A1MAPTTDP1
SCHEMBL5456148 0.75 ALDH1A1 (0.53) HDAC6ALDH1A1HPGDLMNARAB9A
SCHEMBL5452480 0.75 HDAC6 (0.50) HDAC6L3MBTL1ALDH1A1HPGDRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070043062-A1 Isoxazoles as peptide deformylase inhibitors ARPIDA A/S (DK) 2007-02-22 US claimed
EP-1664000-A1 ISOXAZOLES AS PEPTIDE DEFORMYLASE INHIBITORS Arpida A/S (DK) 2006-06-07 EP claimed
WO-2005026133-A1 ISOXAZOLES AS PEPTIDE DEFORMYLASE INHIBITORS ARPIDA A/S (DK) 2005-03-24 WO claimed
US-20070043062-A1 Isoxazoles as peptide deformylase inhibitors ARPIDA A/S (DK) 2007-02-22 US disclosed
US-20070043062-A1 Isoxazoles as peptide deformylase inhibitors ARPIDA A/S (DK) 2007-02-22 US disclosed
US-20070043062-A1 Isoxazoles as peptide deformylase inhibitors ARPIDA A/S (DK) 2007-02-22 US disclosed
EP-1664000-A1 ISOXAZOLES AS PEPTIDE DEFORMYLASE INHIBITORS Arpida A/S (DK) 2006-06-07 EP disclosed
WO-2005026133-A1 ISOXAZOLES AS PEPTIDE DEFORMYLASE INHIBITORS ARPIDA A/S (DK) 2005-03-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070043062-A1 Isoxazoles as peptide deformylase inhibitors PDF, MRPL21, PEPD THRB 1576/4885DAO 476/4885HDAC6 184/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.